Market Report Details Rise in Counterfeit Cognitive Supplements Labeled as Memopezil
A May 28, 2026 market analysis reports increased sales of unauthorized cognitive supplements sold under the Memopezil name. The report outlines differences between the authentic product and counterfeit versions.
manilatimes.netA market analysis released May 28, 2026, states that unauthorized sellers are distributing counterfeit versions of the dietary supplement Memopezil through third-party online platforms. The analysis indicates that authentic Memopezil contains a disclosed blend of Branched-Chain Amino Acids, Bacopa Monnieri, Rhodiola Rosea, L-Theanine, and Panax Ginseng.
It is manufactured in an FDA-registered facility in the United States.
Counterfeit versions reportedly contain undisclosed fillers, incorrect dosages, or different ingredients. The analysis states these versions lack verified manufacturing origins. GEX Corp, identified as the Memopezil manufacturer, has issued repeated consumer warnings about unauthorized listings and advised buyers to verify authenticity through official channels.
The analysis notes that Donepezil, sold under the brand name Aricept, is a prescription acetylcholinesterase inhibitor approved by the FDA for treating dementia symptoms associated with Alzheimer's disease. It requires physician oversight and is not available over the counter.
Memopezil is regulated as a dietary supplement under the Dietary Supplement Health and Education Act of 1994 and is not approved to treat, cure, or prevent any disease.
Transparency
Story details
Related Stories
nbcnews.comStates Sue to Block Paramount-Skydance Acquisition of Warner Bros.
California, New York and other states are preparing legal action against the $110 billion deal. The challenge targets competition and content distribution concerns.
benzinga.comAssembly Biosciences Director Jeanine W. Ajaka Departs Board
Assembly Biosciences reported the resignation of independent director Jeanine W. Ajaka from its board of directors effective June 4 2026. The departure reduces the company's board size and triggers standard SEC and Nasdaq disclosure and governance compliance steps.
prnewswire.comCarlyle Group Elects New Director Following Shareholder Vote
Carlyle Group Inc. reported the election of a new board member and the departure of another at its annual shareholder meeting. The changes alter the composition of the board that oversees the firm's $426 billion asset management portfolio.